Generalizing conditional average treatment effects from nested randomized trials to all trial-eligible individuals

Lan Wen, Issa J. Dahabreh, Yu-Han Chiu · 2026

Read Generalizing conditional average treatment effects from nested randomized trials to all trial-eligible individuals by Lan Wen, Issa J. Dahabreh, Yu-Han Chiu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2605-14952.txt.

Introduction

For trials whose volunteers differ from the wider eligible population, Lan Wen, Issa J. Dahabreh, and Yu-Han Chiu estimate treatment effects that vary with patient traits. Average effects can hide differences that matter for clinical and policy choices. The team builds pseudo-outcomes from conditional influence functions, then fits the effect curve by local linear regression. Sample splitting guards against overfitting, and simulations plus a heart-surgery study illustrate the method.

Catalog record

CREATORLan Wen, Issa J. Dahabreh, Yu-Han Chiu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41065
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2605.14952

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Generalizing conditional average treatment effects from nested randomized trials to all trial-eligible individuals Lan Wen, Issa J. Dahabreh, Yu-Han Chiu Abstract Randomized controlled trials often enroll participants whose characteristics differ from those of a target population, which can limit the generalizability of the estimated treatment effects when effect modifiers differ across populations. While existing generalizability methods primarily focus on estimating the average treatment effect (ATE) in the target population, such summaries may obscure important heterogeneity that is relevant for clinical and policy decision-making. In this work, we illustrate an approach for estimating the conditional average treatment effect (CATE) in a target population of trial-eligible individuals as a function of pre-specified effect modifiers within a nested trial setting. Our approach combines semiparametric theory with flexible estimation: we first estimate nuisance functions using data-adaptive methods and construct pseudo-outcomes from conditional influence functions, then estimate the CATE function via local linear (kernel) regression. Sample splitting and cross-fitting are used to reduce overfitting bias and ensure asymptotic valid inference. Finite-sample performance is assessed via simulations and illustrated in the Coronary Artery Surgery Study (CASS). Keywords: conditional average treatment effect; conditional influence functions; data integration; generalizability; nested trial design; randomized controlled trials. 1 Introduction In randomized controlled trials, the primary estimand that is often reported is the average treatment effect (ATE). In many applications, however, investigators are interested not only in the overall treatment effect in the study population, but also in how treatment effects vary across individuals with different baseline characteristics. Such treatment effect heterogeneity is commonly summarized through the conditional average treatment effect (CATE), which characterizes treatment effects as a function of selected effect modifiers ( Kent et al., 2010 ; Kent et al., 2016 ; Dahabreh et al., 2016 ; Tipton, 2021 ; Inoue et al., 2024 ) . At the same time, participants enrolled in trials are often not representative of the broader target population of trial-eligible individuals. When key effect modifiers of the treatment effect differ between the trial and the target population, the treatment effect estimated within the trial may not be applicable to the population in which treatment decisions are ultimately made ( Cole and Stuart, 2010 ; Stuart et al., 2011 ; Lesko et al., 2017 ) . For instance, the Coronary Artery Surgery Study (CASS), a randomized trial nested within a broader cohort of trial-eligible individuals ( Dahabreh et al., 2019 ) , identified prior myocardial infarction and left ventricular function as key effect modifiers of the treatment effect ( CASS Principal Investigators, 1984 ) . In such settings, investigators may wish to generalize treatment effect heterogeneity estimated among trial participants to the broader trial-eligible individuals. The literature on generalizability or transportability has primarily focused on extending the ATE from randomized trials to the target population of interest ( Cole and Stuart, 2010 ; Stuart et al., 2011 ; Westreich et al., 2017 ; Lesko et al., 2017 ; Rudolph and Laan, 2017 ; Buchanan et al., 2018 ; Dahabreh et al., 2019 ; Dahabreh et al., 2020 ; Colnet et al., 2024 ; Ung et al., 2025 ) , while comparatively less attention has been given to the CATE in this setting ( Seamans et al., 2021 ) . Existing approaches for generalizing CATE to a target population have focused on subgroup-specific average treatment effects defined by a small number of discrete (or discretized) covariates, or regression-based methods that rely on parametric specification of nuisance functions and the CATE model ( Mehrotra et al., 2021 ; Robertson et al., 2024 ) . These approaches may become difficult to apply when attempting to estimate CATEs as functions of continuous covariates or multiple discrete covariates. In parallel, a growing literature has developed semiparametric and machine learning methods for CATE estimation ( Abrevaya et al., 2015 ; Lee et al., 2017 ; Lechner, 2018 ; Künzel et al., 2019 ; Kennedy et al., 2020 ; Semenova and Chernozhukov, 2021 ; Nie and Wager, 2021 ; Knaus et al., 2021 ; Chernozhukov et al., 2024 ; Inoue et al., 2024 ) . However, these methods typically assume that the study population coincides with the target population and therefore do not directly address selective trial participation or generalizability of findings to a broader population. A key consideration in this setting is distinguishing variables needed to adjust for selective trial participation from variables used to define treatment effect heterogeneity. The former are required to extend inferences from a trial to the target population, while the latter characterize how treatment effects vary within that population. This distinction parallels the separation between confounding adjustment and effect modification in observational studies. In practice, investigators may wish to adjust for a rich set of variables for trial participation while restricting treatment-effect summaries to a smaller set of clinically meaningful effect modifiers, particularly when certain variables may be considered inappropriate or inequitable for guiding treatment recommendations (e.g., socioeconomic status or insurance status). In this article, we adapt semiparametric methods for generalizing the CATE from a randomized trial to a target population of trial-eligible individuals under a nested trial design ( Dahabreh et al., 2021 ) . The proposed approach integrates recent methodological advances in CATE estimation for randomized trial and observational study settings with semiparametric techniques for generalizability analyses. Unlike existing work that separately addresses generalizability and flexible estimation of CATE, we develop a unified framework for generalizing CATE from trial participants to a target population under a nested trial design. Building on conditional influence function-based methods ( Chernozhukov et al., 2024 ) , we propose a flexible estimator for the target population CATE. In the first stage, we estimate the necessary nuisance components using flexible data-adaptive (machine learning) methods and use these estimates to construct pseudo-outcomes whose conditional expectation corresponds to the target population CATE. In the second stage, we regress the pseudo-outcomes on the selected effect modifiers using local linear (kernel) regression to obtain a smooth approximation of the CATE function. This approach allows continuous and multivariate effect modifiers without requiring discretization or parametric specification of the CATE function. To ensure valid inference, we use sample splitting and cross-fitting so that the impact of nuisance function estimation on the asymptotic distribution of the final estimator is negligible. We evaluate the finite-sample performance of the methods through simulation studies, and illustrate the method using data from CASS. 2 Notation and setup Consider a trial nested in a cohort of trial-eligible individuals, such as when trial participants are recruited from a broader registry of trial-eligible individuals ( Dahabreh et al., 2021 ) . Let \mathcal{A}=\{a,a^{\prime}\} denote the set of treatments values evaluated in the randomized trial, and S denote an indicator of trial participation (i.e., S=1 for randomized individuals; S=0 for non-randomized trial-eligible individuals). Similar to other generalizability analyses, we assume that baseline covariate information ( X ) is available from all individuals in the cohort ( S\in\{0,1\} ), whereas treatment assignment ( A ) and outcome ( Y ) information is only available from randomized trial participants ( S=1 ). Treatment and outcome data are not required for non-randomized individuals ( S=0 ), as they may be unavailable or deemed less reliable. For simplify exposition, we assume that full adherence to assigned treatment, no measurement

Read the complete text